Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H9NO3 |
| Molecular Weight | 179.1727 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(C=C1)C(O)=O
InChI
InChIKey=QCXJEYYXVJIFCE-UHFFFAOYSA-N
InChI=1S/C9H9NO3/c1-6(11)10-8-4-2-7(3-5-8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)
| Molecular Formula | C9H9NO3 |
| Molecular Weight | 179.1727 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.medicines.org.uk/emc/medicine/27089Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Acedoben (4-acetamidobenzoic acid) is a benzoic acid derivative and a metabolite of benzocaine. It is a component of immunomodulatory drug inosine pranobex, which is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
| Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
| Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. | 2015-06 |
|
| Regioselective carboxylation of catechol by 3,4-dihydroxybenzoate decarboxylase of Enterobacter cloacae P. | 2010-05 |
|
| Ambiguity aversion in rhesus macaques. | 2010 |
|
| Striatal BOLD Response Reflects the Impact of Herd Information on Financial Decisions. | 2010 |
|
| Following gaze: gaze-following behavior as a window into social cognition. | 2010 |
|
| Coordinated scaling of cortical and cerebellar numbers of neurons. | 2010 |
|
| Rhesus monkeys' valuation of vocalizations during a free-choice task. | 2009-11-18 |
|
| General intelligence in another primate: individual differences across cognitive task performance in a New World monkey (Saguinus oedipus). | 2009-06-17 |
|
| Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. | 2009-05-06 |
|
| Individual differences in Scanpaths correspond with serotonin transporter genotype and behavioral phenotype in rhesus monkeys (Macaca mulatta). | 2009 |
|
| The human brain in numbers: a linearly scaled-up primate brain. | 2009 |
|
| Simultaneous determination of p-aminobenzoic acid and its metabolites in the urine of volunteers, treated with p-aminobenzoic acid sunscreen formulation. | 2007-03-12 |
|
| Separate coding of different gaze directions in the superior temporal sulcus and inferior parietal lobule. | 2007-01-09 |
|
| Ketoprofen-inhibited N-acetyltransferase activity and gene expression in human colon tumor cells. | 2006-04-20 |
|
| Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. | 2005-04-01 |
|
| PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS). | 2004-03-16 |
|
| Metabolites of a blocked chloramphenicol producer. | 2003-01 |
|
| Toxicology and carcinogenesis studies of p-nitrotoluene (CAS no. 99-99-0) in F344/N rats and B6C3F(1) mice (feed studies). | 2002-05 |
|
| Contribution of hydrogen bonding to protein stability estimated from isotope effects. | 2002-02-19 |
|
| Effects of butylated hydroxyanisole and butylated hydroxytoluene on DNA adduct formation and arylamine N-acetyltransferase activity in human bladder tumour cells. | 2002-01-25 |
|
| [Quantitative assay of metabolic rate of para-aminobenzoic acid combining glycine for the assessment of rabbit liver function]. | 2001-08 |
|
| Effects of the butylated hydroxyanisole and butylated hydroxytoluene on the DNA adduct formation and arylamines N-acetyltransferase activity in human colon tumor cells. | 2001-06-09 |
|
| Ellagic acid inhibited 2-aminofluorene and p-aminobenzoic acid acetylation by mononuclear leucocytes from Sprague-Dawley rats. | 2001 |
|
| Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. | 1997-12-05 |
|
| Quantification of benzocaine and its metabolites in channel catfish tissues and fluids by HPLC. | 1997-09 |
|
| Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection. | 1993-06 |
|
| Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. | 1986-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/27089
Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857
Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:39:51 GMT 2025
by
admin
on
Wed Apr 02 09:39:51 GMT 2025
|
| Record UNII |
04Z20NMK31
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C73539
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
209-114-7
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL112687
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
4002
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
ACEDOBEN
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
SUB05203MIG
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
C74109
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
DTXSID5024392
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
DB04500
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
556-08-1
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
19266
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
04Z20NMK31
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
46171
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
100000087909
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY | |||
|
4688
Created by
admin on Wed Apr 02 09:39:51 GMT 2025 , Edited by admin on Wed Apr 02 09:39:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |